Zars Pharma has licensed the European sales and marketing rights of Rapydan (70mg lidocaine/70mg tetracaine medicated plaster) to Eusa Pharma. Eusa Pharma began launching Rapydan in other EU countries in early 2008.
Robert Lippert, president and CEO of Zars Pharma, said: “We are pleased to announce the approval of Rapydan in a number of European Union countries with a uniquely positioned commercial partner. Rapydan is the first anesthetic patch innovation to be approved in over a decade that works faster than the current standard of care and will soon become a best-in-class therapy for patients undergoing painful needle procedures.”